Product image of Zilbrysq (Zilucoplan) supplied by GNH India

Zilbrysq

Active Ingredient:
Zilucoplan
Origin:
EU

Zilbrysq (Zilucoplan)

Zilbrysq (zilucoplan) is a subcutaneous therapy for generalized myasthenia gravis, a rare autoimmune disorder. This overview covers its role in symptom management and treatment support. Zilbrysq is designed for adults with confirmed gMG, offering an alternative to daily oral options. zilucoplan injection 10 mg uses include targeted complement inhibition for symptom control.

Manufacturer / TM Owner

Ucb Pharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

Indications & Clinical Uses

  • Zilbrysq (zilucoplan) is prescribed for adults with generalized myasthenia gravis to reduce symptom severity and improve daily function. It works by targeting the complement system, a part of the immune response involved in muscle weakness. Patients often ask, 'what is zilucoplan used for' when exploring therapies for gMG symptom management. This treatment supports stable muscle strength and may reduce reliance on rescue therapies.

Side Effects

  • Users may notice improved muscle strength and reduced fatigue during daily activities after starting zilucoplan. Some report fewer sudden symptom flares, which can support consistent participation in work or social routines. Individual responses vary, and effects build over time with regular use.

Precautions & Warnings

  • Store zilucoplan in the refrigerator until use, protecting it from light and avoiding freezing. Allow the prefilled syringe to reach room temperature for 30 minutes before injection to reduce discomfort. Always follow the handling instructions provided with each dose to maintain sterility and effectiveness.

Avoid Interactions

  • Zilucoplan has not been studied with all drug classes; consult a healthcare provider before combining with immunosuppressants or other biologics. Alcohol and certain supplements may influence immune response or injection tolerance. No known food interactions affect zilucoplan’s activity, but discuss any new medications or supplements during treatment planning.

Frequently Asked Questions

Zilucoplan is given as a subcutaneous injection, typically self-administered after training by a healthcare professional.

Common side effects may include injection-site reactions, headache, or upper respiratory infections.

It may be used alongside other therapies, but a healthcare provider should review the full treatment plan for safety.

It is approved for adults with generalized myasthenia gravis; suitability depends on individual diagnosis and medical history.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Zilucoplan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT